Nutriband Inc. (NASDAQ: NTRB), a leader in the development of prescription transdermal pharmaceutical products, has reached a critical milestone in its mission to combat the opioid crisis. The U.S. Food and Drug Administration (FDA) has scheduled a Type C Meeting for September 18, 2025, to review the Chemistry, Manufacturing, and Controls (CMC) plans for its innovative product, AVERSA(TM) Fentanyl. This meeting represents a significant step forward in the approval process for what could become the world's first abuse-deterrent opioid patch.
Developed in collaboration with Kindeva, AVERSA(TM) Fentanyl integrates Nutriband's proprietary abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch. This groundbreaking combination aims to prevent abuse, diversion, misuse, and accidental exposure, while ensuring that patients in need retain access to essential pain management solutions. The potential impact of this technology on public health is substantial, given the ongoing opioid epidemic in the United States and beyond.
The AVERSA(TM) technology is not only innovative but also widely protected, with patents secured in 46 countries. Nutriband estimates that the U.S. market alone could see peak annual sales of AVERSA(TM) Fentanyl ranging from $80 million to $200 million, with plans for global expansion in the future. This positions the product as a key player in the pharmaceutical industry's efforts to address opioid abuse.
For more information on Nutriband's developments, visit https://ibn.fm/GGIyr. Investors and stakeholders can stay updated on Nutriband's progress by following the company's newsroom at https://ibn.fm/NTRB.
The significance of the FDA's upcoming meeting cannot be overstated. It underscores the urgent need for innovative solutions to the opioid crisis and highlights Nutriband's role in pioneering abuse-deterrent technologies. As the pharmaceutical industry continues to grapple with the challenges of opioid abuse, AVERSA(TM) Fentanyl represents a beacon of hope for reducing the harm associated with these powerful medications.
